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Prostate cancer is a leading cause of cancer-related death in males
and is second only to lung cancer. Although effective surgical and
radiation treatments exist for clinically localized prostate cancer,
metastatic prostate cancer remains essentially incurable. Here we
show, through gene expression profiling1, that the polycomb
group protein enhancer of zeste homolog 2 (EZH2)2,3 is over-
Figure 1 Overexpression of EZH2 in metastatic hormone-refractory prostate cancer
(MET). a, Cluster diagram depicting genes that distinguish MET from clinically localized
prostate cancer (PCA). Genes upregulated in METs relative to prostate cancer are shown.
Red and green represent upregulatiom and downregulation, respectively, relative to the
median of the reference pool. Grey represents technically inadequate or missing data, and
black represents equal expression relative to the reference sample. b, DNA microarray
analysis of prostate cancer shows upregulation of EZH2 in METs. BPH, benign prostatic
hyperplasia; NAT, normal adjacent prostate tissue. c, RT–PCR analysis of the EZH2
transcript in prostate tissue and cell lines. d, Increased expression of EZH2 protein in
METs. Immunoblot analysis of EZH2 and EED in prostate tissue extracts. The site of
metastasis is indicated.
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expressed in hormone-refractory, metastatic prostate cancer.
Small interfering RNA (siRNA) duplexes4 targeted against
EZH2 reduce the amounts of EZH2 protein present in prostate
cells and also inhibit cell proliferation in vitro. Ectopic
expression of EZH2 in prostate cells induces transcriptional
repression of a specific cohort of genes. Gene silencing mediated
by EZH2 requires the SET domain and is attenuated by inhibiting
histone deacetylase activity. Amounts of both EZH2 messenger
RNA and EZH2 protein are increased in metastatic prostate
cancer; in addition, clinically localized prostate cancers that
express higher concentrations of EZH2 show a poorer prognosis.
Thus, dysregulated expression of EZH2 may be involved in the
progression of prostate cancer, as well as being a marker that
distinguishes indolent prostate cancer from those at risk of lethal
progression.
Perturbation of the transcriptional ‘memory’ of a cell can lead to
severe developmental defects5,6. Lack of differentiation, or anaplasia,
is a hallmark of cancer that results from normal cells ‘forgetting’
their cellular identity. Thus, it is not surprising that dysregulation of
the transcriptional maintenance system can lead to malignancy6–8.
Two groups of proteins have been implicated in maintaining
homeotic gene expression and include polycomb (PcG) and
trithorax (trxG) group proteins9,10. PcG proteins act in large com-
plexes and are thought to repress gene expression, whereas trxG
proteins are operationally defined as antagonists of PcG proteins
and thus activate gene expression6,9. In human malignancies, PcG
and trxG proteins have been found to be dysregulated mainly in cells
of haematopoietic origin11–13. EZH2 is the human homologue of the
Drosophila protein Enhancer of Zeste (E(z))2, which genetic data
define as a PcG protein with additional trxG properties10. E(z) and
EZH2 contain a SET domain, a highly conserved domain found in
chromatin-associated regulators of gene expression that often
modulate cell growth pathways14.
We previously reported gene expression profiles of benign pros-
tate, clinically localized prostate cancer and metastatic prostate
cancer1. To characterize genes that specifically mark the molecular
transition from organ-confined prostate cancer to metastatic pros-
tate cancer, we implemented a statistical technique called signifi-
cance analysis of microarrays (SAM)15. This approach identified 55
genes that were significantly upregulated (Fig. 1a) and 480 genes
that were significantly downregulated (Supplementary Infor-
mation) in metastatic prostate cancer relative to localized prostate
cancer (at a false discovery rate (FDR) of 0.9% on microarrays
containing 10,000 genes). Notably, the gene at the top of the ‘list’ of
upregulated genes in metastatic prostate cancer was EZH2, with a d-
score15 of 4.58 and a gene-specific FDR of 0.0012 (see Supplemen-
tary Information for the complete SAM analysis). Fig. 1b summar-
izes the gene expression of EZH2 in 74 prostate tissue specimens
analysed on DNA microarrays1. The EZH2 transcript was signifi-
cantly increased in metastatic prostate cancer with respect to
clinically localized prostate cancer (Mann–Whitney test,
P ¼ 0.001) and benign prostate (P ¼ 0.0001).
To validate the DNA microarray results, we carried out poly-
merase chain reaction with reverse transcription (RT–PCR) on 18
prostate samples and cell lines. As expected, the levels of EZH2
mRNA were increased in malignant relative to benign prostate
Figure 2 Amounts of EZH2 protein correlate with the aggressiveness of prostate cancer.
a, Representative tissue microarray elements stained with antibody to EZH2.
Immunohistochemical stains show weak or absent nuclear staining of benign prostate
cancer (left, original magnification £ 100), and strong nuclear staining in metastatic
hormone-refractory prostrate cancers (centre right and right, original magnification
£ 100 and £ 1,000, respectively). Also shown is a benign prostate adjacent to prostate
cancer (centre left, original magnification £ 100). b, Tissue microarray analysis of EZH2
expression. The mean EZH2 protein expression for the indicated prostate tissues is
summarized using error bars with 95% confidence intervals. c, Kaplan–Meier analysis
shows that individuals with clinically localized prostate cancer that have high expression of
EZH2 (moderate to strong staining) have a greater risk for recurrence of prostate cancer
after prostatectomy (log rank test, P ¼ 0.03).
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samples (Fig. 1c). We also analysed tissue extracts by immunoblot-
ting. The amounts of EZH2 protein were markedly increased in
metastatic prostate cancer relative to localized prostate cancer or
benign prostate (Fig. 1d). Notably, EED, a PcG protein that forms a
complex with EZH2 (refs 16, 17), did not show similar protein
dysregulation.
We evaluated the expression of EZH2 protein in a wide range of
prostate tissues (n ¼ 1,023 tissue microarray elements) to deter-
mine the extent of its expression in situ (Fig. 2a, b). Of these
samples, 400 were from 23 individuals who died of hormone-
refractory metastatic prostate cancer18. When highly expressed,
EZH2 was observed mainly in the nucleus (Fig. 2a, right), as
suggested previously11. The intensity of EZH2 staining increased
from benign, prostatic atrophy, prostatic intraepithelial neoplasia,
to clinically localized prostate cancer, with a respective median
staining intensity of 1.5 (standard error (s.e.) 0.04, 95% confidence
interval (CI) 1.4–1.6), 1.6 (s.e. 0.2, 95%CI 1.3–2.0), 2.3 (s.e. 0.2,
95%CI 1.9–2.7) and 2.6 (s.e. 0.1, 95%CI, 2.5–2.7), respectively (Fig.
2b). The strongest EZH2 expression was in metastatic prostate
cancer, with a median staining intensity of 3.1 (s.e. 0.03, 95%CI 3.0–
3.2). There was a statistically significant difference in EZH2 staining
intensity between benign prostate tissue and localized prostate
cancer (analysis of variance (ANOVA) post-hoc analysis mean
difference 1.0, P , 0.0001). Likewise, metastatic prostate cancer
had significantly higher expression of EZH2 than did clinically
localized prostate cancer (ANOVA post-hoc analysis mean differ-
ence 0.5, P , 0.0001). These findings suggested that as prostate
neoplasia progresses there is a trend towards increased expression of
EZH2 protein. They also suggested that EZH2 concentrations might
indicate how aggressive an individual’s prostate cancer is, given that
the highest expression was observed in hormone-refractory, meta-
static prostate cancer.
We therefore examined whether EZH2 protein could be used to
predict clinical outcome in men treated with surgery for clinically
localized prostate cancer. Using a previously validated tissue micro-
array19, we examined 278 specimens from 64 individuals with
clinical follow-up. To test the utility of EZH2 as a potential tissue
biomarker for prostate cancer, we examined the clinical outcome of
these 64 cases, taking into account clinical and pathological par-
ameters. Clinical failure was defined as either an increase of
0.2 ng ml21 prostate-specific antigen (PSA) or recurrence of disease
after prostatectomy (for example, development of metastatic dis-
ease).
By Kaplan–Meier analysis (Fig. 2c), an EZH2 staining intensity of
3 or higher was associated significantly with clinical failure in 31%
(10/32) of individuals (log rank P ¼ 0.03), whereas a staining
intensity of less than 3 was found in 9% (3/32) of individuals
with clinical failure. There was no significant correlation between
EZH2 amounts and Gleason score, tumour stage or surgical margin
status. Notably, there was a significant (P ¼ 0.048) albeit weak
(Pearson coefficient ¼ 0.33) correlation between EZH2 protein and
proliferation index in situ, as assessed by the Ki-67 labelling index
(Supplementary Information). Multivariable Cox hazards
regression analysis showed that EZH2 protein expression ($3
versus ,3) was the best predictor of clinical outcome with a
recurrence ratio of 4.6 (95%CI 1.2–17.1, P ¼ 0.02), which was
significantly better than surgical margin status, maximum tumour
dimension, Gleason score and pre-operative PSA (Supplementary
Information). Thus, monitoring the amounts of EZH2 protein in
prostate specimens may provide additional prognostic information
that is not discernible with current clinical and pathology par-
ameters alone.
To examine the role of EZH2 in prostate cancer progression, we
used RNA interference (RNAi) to disrupt EZH2 expression in
transformed prostate cells in vitro. We designed duplexes of 21-
nucleotide RNA (siRNAs) to target EZH2 (ref. 4) and tested them
on the transformed androgen-responsive prostate cell line
RWPE20,21 and the metastatic prostate cancer cell line PC3. After
Figure 3 A role for EZH2 in prostate cell proliferation. a, Immunoblot analysis of prostate
cells (RWPE, PC3) incubated with EZH2 siRNA duplexes. Sense and antisense
oligonucleotides of EZH2 and unrelated siRNA duplexes were used as controls. b, RNAi of
EZH2 decreases cell proliferation, as assessed by cell counting assay after 48 h of
incubation with EZH2 siRNA. Significant inhibition of growth is seen in cells treated with
EZH2 siRNA relative to those treated with unrelated controls (Student’s t-test,
P , 0.001). Data are from two independent experiments carried out in quadruplicate.
c, Time course of growth inhibition by EZH2 siRNA. RWPE cells were treated with
EZH2 or luciferase siRNA for indicated time periods and the cells were counted. d, RNAi
of EZH2 inhibits cell proliferation, as assessed by WST assay. EZH2 siRNA significantly
inhibited cell proliferation as compared with controls (Student’s t-test, P , 0.001).
e, RNAi of EZH2 induces cell-cycle arrest of prostate cells as assessed by flow
cytometry.
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48 h of transfection with siRNA duplexes, quantification of the
amounts of endogenous EZH2 protein showed a specific down-
regulation of protein in prostate cell lines (Fig. 3a). Sense or
antisense oligonucleotides, as well as unrelated siRNA duplexes,
did not affect the amounts of EZH2 (Fig. 3a, middle and right),
verifying the specificity of the siRNA approach.
We next examined the phenotype of the prostate cells with
reduced EZH2 expression. RWPE cell counts taken 48 h after
transfection with siRNA showed a marked (62%) inhibition of
cell growth caused by the EZH2 siRNA duplex, whereas the
corresponding sense and antisense EZH2 oligonucleotides or unre-
lated duplexes showed minimal inhibition (Fig. 3b). The PC3
prostate cancer cell line showed a similar growth inhibition
by EZH2 siRNA, indicating that these findings were not specific
to the RWPE cell line (Fig. 3b). The effect of EZH2 siRNA on
prostate cell growth was monitored at time points ranging from 24
to 120 h (Fig. 3c), during which over 80% growth inhibition was
observed.
Using a commercially available cell proliferation reagent WST-1,
which measures mitochondrial dehydrogenase activity, we observed
a decrease in cell proliferation in cells transfected with the EZH2
siRNA duplex but not with the unrelated duplexes (Fig. 3d). In the
time frame considered (48 h), RNAi of EZH2 did not induce
apoptosis, as assessed by propidium iodide staining of nuclei or
cleavage of poly(adenosine diphosphate)-ribosylpolymerase (data
not shown). Consistent with this, the broad-spectrum caspase
inhibitor, zVAD-fmk, failed to attenuate the inhibition of cell
proliferation induced by EZH2 siRNA (Fig. 3d). Notably, flow
cytometric analysis of prostate cells treated with EZH2 siRNA
showed cell-cycle arrest in the G2/M phase (Fig. 3e). Unrelated
control siRNA duplexes failed to induce a similar dysregulation of
the cell cycle. Together, these observations indicate that EZH2 may
be involved in the proliferation of prostate cells by mitigating the
G2/M transition.
To understand further the functional role of EZH2 in prostate
cells, we generated an epitope-tagged version of wild-type EZH2
and a deletion mutant of EZH2 lacking the conserved SET domain14
in the eukaryotic expression vector, pcDNA3 (Fig. 4a, b). We also
designed an ‘inducible’ version22,23 of EZH2 by creating a fusion
protein with a modified murine oestrogen receptor (ER; Fig. 4a, b).
PcG proteins have been proposed to mediate their functions by
repressing target genes2,5. To test this hypothesis, we transiently
transfected RWPE prostate cells with wild-type EZH2 and mon-
itored alterations in global gene expression using DNA microarrays.
The RNA from the transfected cell line was labelled with one
fluorescent dye, whereas the paired reference sample was labelled
with a second distinguishable fluorescent dye. By making direct
comparisons between ‘gene’-transfected cell lines and cells lines
transfected with control vector, we emphasized the molecular
differences between the samples and obviated the need for complete
transfection efficiency.
When EZH2 was overexpressed in RWPE cells or SUM149 breast
carcinoma cells, there was a consistent repression of a cohort of
genes (Fig. 4c, d). When compared with vector-transfected cells, the
only gene that was upregulated significantly in EZH2-transfected
cells was EZH2 itself (Fig. 4c). The EZH2-mediated transcriptional
repression was dependent on an intact SET domain (Fig. 4c),
because deletion of this domain did not produce a repressive
phenotype and in some cases ‘de-repressed’ genes. EZH2 interacts
with histone deacetylase 2 (HDAC2) through the EED protein24,
and in our system EZH2-mediated gene silencing was dependent on
HDAC activity, because the commonly used HDAC inhibitor
trichostatin A (TSA) completely abrogated the effects of EZH2
(Fig. 4c). Thus, EZH2 function requires both an intact SET domain
and endogenous HDAC activity.
To identify genes that are significantly repressed by EZH2, we
compared cells transfected with wild-type EZH2 with cells trans-
Figure 4 EZH2 functions as a transcriptional repressor in prostate cells. a, EZH2
constructs. CYS, cysteine-rich domain; ER, ligand-binding domain of the oestrogen
receptor; H-I and H-II, homology domains that share similarity with E(z); NLS, nuclear
localization signal; SET, SET domain; TAG, Myc epitope tag. b, Expression of the EZH2
constructs. c, Cluster diagram of genes significantly repressed by overexpression of
EZH2. See Fig. 1a for the matrix colour scheme and Supplementary Information for the
complete data set. TAM, tamoxifen; TSA, trichostatin A. d, SAM analysis15 of gene
expression profiles of cells transfected with EZH2 versus cells transfected with
EZH2DSET.
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fected with EZH2DSET. We found that 163 genes were consistently
repressed, whereas no genes were activated at an FDR of 0.0045
(Fig. 4d, and Supplementary Information). The list of genes that
were repressed indicates several intriguing associations, including
EZH2-mediated repression of specific PcG proteins, transcription
factors and cell-cycle regulators (Supplementary Information).
In summary, we have identified the association of EZH2 with
advanced prostate cancer by gene expression profiling of tumour
specimens from individuals who died of metastatic disease. Measur-
ing EZH2 amounts (in prostate cancer specimens) might have
potential as a molecular determinant of prostate cancer progression
and metastasis. In addition, we have shown that EZH2 has a role in
mediating cell proliferation and transcriptional repression in pros-
tate cells. Overall, our study indicates that dysregulation of the
transcriptional memory machinery may contribute to the lethal
progression of prostate cancer and may provide a potential mecha-
nism for the constellation of genes repressed in metastatic disease.A
Methods
SAM analysis of prostate cancer gene expression
We carried out SAM analysis by comparing gene expression profiles of metastatic prostate
cancer samples with those of clinically localized prostate cancer samples from our previous
work1. Genes were analysed using Cluster25, implementing average linkage hierarchical
clustering of genes, and the output (Supplementary Information) was visualized by
Treeview25.
RT–PCR
We carried out RT–PCR amplifications with 1 mg of total RNA isolated from the indicated
prostate tissues and cell lines. Primer sequences are given in the Supplementary
Information.
Immunoblot analysis
Prostate tissue extracts were separated by SDS–PAGE and blotted onto nitrocellulose
membranes. Antibodies against EZH2 and EED (ref. 17) and a polyclonal antibody against
b-tubulin (Santa Cruz) were used at 1:1,000 dilution for immunoblot analysis.
Tissue microarray analysis
The clinically stratified prostate cancer tissue microarrays used in this study have been
described1,19,26. Tissues were from the radical prostatectomy series at the University of
Michigan and from the Rapid Autopsy Program, which are both part of Michigan Prostate
SPORE Tissue Core. We obtained Institutional Review Board approval to procure and
analyse the tissues used in this study.
We evaluated EZH2 protein expression on a wide range of prostate tissue to determine
the intensity and extent of expression in situ. Immunohistochemistry was carried out on
three high-density tissue microarrays containing samples of benign prostate, prostatic
atrophy, prostatic intraepithelial neoplasia, clinically localized prostate cancer and
metastatic prostate cancer. We used standard biotin–avidin complex
immunohistochemistry to evaluate EZH2 protein expression using an antibody against
EZH2. Protein expression was scored as negative (score ¼ 1), weak (2), moderate (3) and
strong (4). Four replicate tissue cores were sampled from each of the selected tissue types.
EZH2 expression was evaluated in a blind manner separately by M.A.R. and M.Z. using a
validated web-based tool26,27, and the median value of all measurements from a single
individual was used for subsequent analysis. Staining assessment was highly reproducible
between the two pathologists with a k value of 0.73.
Clinical outcomes analysis
To assess individual variables for risk of recurrence, we used Kaplan–Meier survival
analysis and created a univariate Cox proportional hazards model. PSA recurrence was
defined as greater than 0.2 ng ml21 after radical prostatectomy. Covariates included
Gleason sum, preoperative PSA, maximum tumour dimension, tumour stage and surgical
margin status. To assess the influence of several variables simultaneously, including EZH2
protein expression, we developed a final multivariate Cox proportional hazards model of
statistically significant covariates. Statistical significance in univariate and multivariate
Cox models was determined by Wald’s test. A P value of less than 0.05 was considered
statistically significant.
EZH2 constructs
Myc-tagged EZH2–pCMV was a gift from T. Jenuwein. The Myc–EZH2 fragment was
subcloned into the expression vector pCDNA3 (Invitrogen). The EZH2–ER and
EZH2DSET constructs are described in the Supplementary Information.
RNAi
We chemically synthesized 21-nucleotide sense and antisense RNA oligonucleotides
(Dharmacon) and annealed them to form duplexes. The EZH2 siRNA was targeted to the
region corresponding to residues 85–106 of human EZH2 (NM004456). Control siRNA
duplexes targeted luciferase, lamin and AMACR (NM014324). The human transformed
prostate cell lines RWPE20 and PC3 were plated at 2 £ 105 cells per well in a 12-well plate
for immunoblot analysis, cell counts and FACS analysis, and at 1.5 £ 104 cell per well in a
96-well plate for WST-1 proliferation assays. Twelve hours after plating, the cells were
transfected with 60 pmol of siRNA duplex, sense or antisense oligonucleotides using
oligofectamine (Invitrogen). We carried out a second identical transfection 24 h later. At
certain time points after the first transfection, the cells were lysed for immunoblot analysis
and treated with trypsin for estimating cell numbers or FACS analysis. For cell counts at 96
and 120 h, the cells were treated with trypsin and replated in 6-well dishes 64 h after the
first transfection.
Cell proliferation assays
Cell proliferation was determined by a colorimetric assay of cell viability that is based on
the cleavage of the tetrazolium salt WST-1 by mitochondrial dehydrogenases (Roche). The
absorbance of the formazan dye formed, which correlates with the number of
metabolically active cells in the culture, was measured at 450 nm 1 h after adding the
reagent. Cell counts were estimated by treating the cells with trypsin, followed by analysis
on a Coulter cell counter at specified time points.
Flow cytometric analysis
Trypsin-treated cells were washed with PBS and fixed in 70% ethanol overnight for FACS
analysis. Before staining with propidium iodide, the cells were washed again with PBS and
analysed by flow cytometry.
Microarray analysis of EZH2-transfected cells
Initial testing of the transient transfection analysis system (data not shown) showed that
overexpression of TNFR1 (p55) induced similar expression profiles to those observed after
incubating cells with TNF28. Samples expressing the EZH2DSET mutant were compared
with those expressing EZH2 using the SAM analysis package (ref. 15 and Supplementary
Information).
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Semaphorins are a family of phylogenetically conserved soluble
and transmembrane proteins1,2. Although many soluble sema-
phorins deliver guidance cues to migrating axons during neur-
onal development3–5, some members are involved in immune
responses6–9. For example, CD100 (also known as Sema4D), a
class IV transmembrane semaphorin, signals through CD72 to
effect nonredundant roles in immune responses7,10–13 in a ligand–
receptor system that is distinct from any seen previously in the
nervous system14,15. Here we report that the class IV semaphorin
Sema4A, which is expressed in dendritic cells and B cells,
enhances the in vitro activation and differentiation of T cells
and the in vivo generation of antigen-specific T cells. Treating
mice with monoclonal antibodies against Sema4A blocks the
development of an experimental autoimmune encephalomyelitis
that is induced by an antigenic peptide derived from myelin
oligodendrocyte glycoprotein. In addition, expression cloning
shows that the Sema4A receptor is Tim-2, a member of the family
of T-cell immunoglobulin domain and mucin domain (Tim)
proteins that is expressed on activated T cells.
To study the semaphorins expressed in dendritic cells (DCs), we
isolated a complementary DNA fragment of the class IV sema-
phorin, Sema4A, through cloning based on polymerase chain
reaction (PCR) using degenerate oligonucleotide primers derived
from motifs that are conserved among members of the semaphorin
family. Sema4A was originally identified as semB, the expression
of which gradually increases during embryonic development16,
although its functions have not yet been reported. Analysis
by PCR with reverse transcription (RT–PCR) showed that
there was prominent expression of Sema4A messenger RNA in
the brain, spleen, lung, kidney and testis of adult tissues (data not
shown).
To investigate the biological function and expression of
Sema4A in the immune system, we prepared recombinant soluble
mouse Sema4A protein comprising the putative extracellular
region fused to the human immunoglobulin-g1 (IgG1) Fc frag-
ment (Sema4A–Fc). We generated antibodies against Sema4A by
immunizing rats with Sema4A–Fc and screening the hybridomas
for reactivity to mouse Chinese hamster ovary (CHO) cell
transfectants expressing Sema4A (Fig. 1a). The anti-Sema4A
antibody (hereafter referred to as anti-Sema4A) specifically
bound to Sema4A but not to control CHO cells carrying only
the Neomycin resistance plasmid or to CHO cells expressing
CD100. As expected from our cloning methodology, Sema4A
was expressed abundantly on the surface of bone-marrow-derived
and splenic DCs (Fig. 1b). No differences were found in Sema4A
expression between DCs expressing the CD8a antigen and those
not expressing it. Expression of Sema4A was also detected on the
surface of resting B cells but not resting T cells. When B cells were
stimulated with an antibody against CD40 (anti-CD40), the
expression of Sema4A was upregulated. The slight expression of
Sema4A became detectable when T cells were stimulated with an
antibody against CD3 (anti-CD3).
To test whether Sema4A has an effect on T-cell activation, T cells
carrying the CD4 antigen (CD4þ T cells) were stimulated with
immobilized anti-CD3 in the presence of Sema4A–Fc or control
human IgG1. Sema4A–Fc enhanced the T-cell proliferation and
interleukin 2 (IL-2) production induced by anti-CD3 (Fig. 2a). We
next examined whether Sema4A promotes the differentiation of
naive T cells into T-helper 1 (TH1)-like or TH2-like effector
populations under their respective culture conditions17. Addition
of Sema4A–Fc significantly enhanced the induction of cells produ-
cing interferon-g (IFN-g) and cells producing IL-4 (Fig. 2b). We
also examined the effect of Sema4A–Fc on mixed lymphocyte
reactions (MLRs) between allogeneic T cells and DCs. Bone-
marrow-derived DCs on a C57BL/6 background were used to
stimulate BALB/c spleen CD4þ T cells. Sema4A–Fc enhanced
MLRs, including the proliferation of T cells and the production of
IL-2 (Fig. 2c). When fully mature DCs that had been treated with
anti-CD40 and fixed with paraformaldehyde were used as MLR
stimulants, Sema4A–Fc showed an enhancing effect (Fig. 2d),
indicating that Sema4A acts directly on T cells. Anti-Sema4A also
inhibited MLRs between allogeneic T cells and DCs (Fig. 2e),
confirming the involvement of Sema4A in T-cell activation through
interactions between T cells and DCs. Although we have shown
that CD100 enhances the activation of B cells and DCs7,18,
Sema4A–Fc did not possess this activity (Supplementary Infor-
mation Fig. 1).
To determine whether Sema4A is involved in antigen-specific
T-cell responses in vivo, we immunized mice subcutaneously with
keyhole limpet haemocyanin (KLH) in complete Freund’s adjuvant
(CFA) and then treated them intravenously with Sema4A–Fc for
4 d. Five days after immunization, CD4þ T cells were prepared from
the draining lymph nodes and were tested in vitro for antigen-
specific responses. There was a significant increase in proliferation
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